Skip to main content
NCBI home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2010 Jul 7;11(5):379–389. doi: 10.1007/s10194-010-0232-1

Verisimilitude (or “truthlikeness”) as an alternative to pro and cons: migraine and cluster headache mechanisms

Peer Carsten Tfelt-Hansen 1,✉
PMCID: PMC3452275  PMID: 20607582

Abstract

Calculating verisimilitude (or “truthlikeness”) ad modum Popper is a quantitative alternative to the usual pros and cons in migraine and cluster headache mechanisms. The following items were evaluated: dilation of large cranial arteries during migraine; CGRP increase during migraine; migraine as a brain disorder; aura and migraine headache; brain stem activation during migraine; rCBF in migraine without aura; NO and pathophysiology of migraine; neurogenic inflammation and migraine; aura in cluster headache; and hypothalamic activation in cluster headache. It is concluded that verisimilitude calculations can be helpful when judging pathophysiological problems in migraine and cluster headache.

Keywords: Migraine, Cluster headache, Pathophysiology, Mechanism, Verisimilitude

Full Text

The Full Text of this article is available as a PDF (250.4 KB).

Conflict of interest

None.

References

  • 1.Lipton P. The Medawar Lecture 2004 the truth about science. Philos Trans R Soc Lond B Biol Sci. 2005;360:1259–1269. doi: 10.1098/rstb.2005.1660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) induces genuine migraine attacks. Eur J Neurol. 1994;1:73–80. doi: 10.1111/j.1468-1331.1994.tb00053.x. [DOI] [PubMed] [Google Scholar]
  • 3.Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther. 2008;120:157–171. doi: 10.1016/j.pharmthera.2008.08.003. [DOI] [PubMed] [Google Scholar]
  • 4.Afridi SK, Matharu MS, Lee L, Kaube H, Friston KJ, Frackowick RS, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005;128:932–939. doi: 10.1093/brain/awh416. [DOI] [PubMed] [Google Scholar]
  • 5.Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54–61. doi: 10.1046/j.1468-2982.2002.00310.x. [DOI] [PubMed] [Google Scholar]
  • 6.Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport. 1993;4:1027–1030. doi: 10.1097/00001756-199308000-00008. [DOI] [PubMed] [Google Scholar]
  • 7.Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR. Neurobiology of migraine. Neuroscience. 2009;161:327–341. doi: 10.1016/j.neuroscience.2009.03.019. [DOI] [PubMed] [Google Scholar]
  • 8.Popper KR. The logic of scientific discovery. London: Routledge; 1959. [Google Scholar]
  • 9.International Headache Society Clinical Trial Subcommittee (2000) Guidelines for controlled trials of drugs in migraine, vol 20, 2nd edn. Cephalalgia, pp 765–786 [DOI] [PubMed]
  • 10.Tfelt-Hansen P, Vries P, Saxena PR. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259–1287. doi: 10.2165/00003495-200060060-00003. [DOI] [PubMed] [Google Scholar]
  • 11.Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1B agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668–1675. doi: 10.1016/S0140-6736(01)06711-3. [DOI] [PubMed] [Google Scholar]
  • 12.Linde K, Rossnagel K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2:CD003225 [DOI] [PubMed]
  • 13.Sultan A, McQuay HJ, Moore RA, Derry S (2009) Single dose oral flurbiprofen for acute postoperative pain in adults. Cochrane Database Syst Rev (3):CD007358 [DOI] [PMC free article] [PubMed]
  • 14.Popper KR (2003) Conjectures and refutations. The growth of scientific knowledge. Routledge, London
  • 15.Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry. 1938;39:737–763. [Google Scholar]
  • 16.Wolff HG (1963) Headache and other head pain, 2nd edn. Oxford University Press, New York
  • 17.Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral dilatation: reversal by sumatriptan. Lancet. 1991;336:13–17. doi: 10.1016/0140-6736(91)90005-A. [DOI] [PubMed] [Google Scholar]
  • 18.Thomsen LL, Iversen HK, Olesen J. Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia. 1995;15:109–116. doi: 10.1046/j.1468-2982.1995.015002109.x. [DOI] [PubMed] [Google Scholar]
  • 19.Totaro R, De matteis G, Marini C, Balassarre M, Carolei A. Sumatriptan and cerebral blood flow velocity changes during migraine attacks. Headache. 1997;37:635–639. doi: 10.1046/j.1526-4610.1997.3710635.x. [DOI] [PubMed] [Google Scholar]
  • 20.Zwetsloot CP, Caebeke J, Odink J, Ferrari MD. Vascular reactivity during migraine attacks: a transcranial Doppler study. Headache. 1991;31:593–595. doi: 10.1111/j.1526-4610.1991.hed3109593.x. [DOI] [PubMed] [Google Scholar]
  • 21.Zwetsloot CP, Caebeke J, Ferrari MD. Lack of asymmetry of middle cerebral artery blood velocities in unilateral migraine. Stroke. 1993;24:1335–1338. doi: 10.1161/01.str.24.9.1335. [DOI] [PubMed] [Google Scholar]
  • 22.Schoonman GG, Grond J, Kortman C, Geest RJ, Terwindt GM, Ferrari MD. Migraine headache is no associated with cerebral or meningeal vasodilation—a 3T magnetic resonance angiographic study. Brain. 2008;131:2192–2200. doi: 10.1093/brain/awn094. [DOI] [PubMed] [Google Scholar]
  • 23.Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–187. doi: 10.1002/ana.410280213. [DOI] [PubMed] [Google Scholar]
  • 24.Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and in cats. Ann Neurol. 1993;33:48–56. doi: 10.1002/ana.410330109. [DOI] [PubMed] [Google Scholar]
  • 25.Vause CV, Durham PL. Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal neurons and glia cells: findings from array analysis. Cephalalgia. 2009;29(suppl 1):116–117. doi: 10.1016/j.neulet.2010.01.074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005;58:561–563. doi: 10.1002/ana.20605. [DOI] [PubMed] [Google Scholar]
  • 27.Tfelt-Hansen P (2010) Calcitonin gene-related peptide in external jugular vein during migraine and cluster headache. Is it increased? In: Olesen J (ed) Role of calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) in migraine. Frontiers in headache research, vol 17. Oxford University Press (in press)
  • 28.Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004;44:865–872. doi: 10.1111/j.1526-4610.2004.04168.x. [DOI] [PubMed] [Google Scholar]
  • 29.Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA (eds) (2006) The headaches, 3rd edn. Lippincott Williams and Wilkins, Philadelphia, pp 1–1169
  • 30.Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981;9:344–352. doi: 10.1002/ana.410090406. [DOI] [PubMed] [Google Scholar]
  • 31.Lauritzen M, Olsen TS, Lassen NA, Paulson OB. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol. 1983;13:633–641. doi: 10.1002/ana.410130609. [DOI] [PubMed] [Google Scholar]
  • 32.Hajdikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA. 2001;08:4687–4692. doi: 10.1073/pnas.071582498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Weiller C, May A, Limroth V, Jüpter M, Kaube H, Schayck RV, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1:658–660. doi: 10.1038/nm0795-658. [DOI] [PubMed] [Google Scholar]
  • 34.Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Hypothalamic activation in spontaneous migraine attacks. Headache. 2007;47:1418–1425. doi: 10.1111/j.1526-4610.2007.00776.x. [DOI] [PubMed] [Google Scholar]
  • 35.Haas DC, Kent PF, Friedman DI. Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area. Headache. 1993;33:452–455. doi: 10.1111/j.1526-4610.1993.hed3308452.x. [DOI] [PubMed] [Google Scholar]
  • 36.Afridi S, Goadsby PJ. New onset of migraine with a brain stem cavernoma. J Neurol Neurosurg Psychiatry. 2003;74:680–682. doi: 10.1136/jnnp.74.5.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.SchoenenJ Maetens, Noordhout A, Timsit-Berthier M, Timsit M. Contingent negative variation and efficacy of beta-blocking agents in migraine. Cephalalgia. 1986;6:229–233. doi: 10.1046/j.1468-2982.1986.0604229.x. [DOI] [PubMed] [Google Scholar]
  • 38.Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical depression in migraine prophylaxis. Ann Neurol. 2006;59:652–661. doi: 10.1002/ana.20778. [DOI] [PubMed] [Google Scholar]
  • 39.Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT) 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain. 1997;120:2171–2177. doi: 10.1093/brain/120.12.2171. [DOI] [PubMed] [Google Scholar]
  • 40.Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia. 2004;24:1049–1056. doi: 10.1111/j.1468-2982.2004.00767.x. [DOI] [PubMed] [Google Scholar]
  • 41.Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol. 1993;109:788–792. doi: 10.1111/j.1476-5381.1993.tb13643.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Hoskin KL, Bulmer DC, Goadsby PJ. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett. 1999;266:173–176. doi: 10.1016/S0304-3940(99)00281-5. [DOI] [PubMed] [Google Scholar]
  • 43.Goadsby PJ, Hoskin KL. Differential effects of low dose CP122, 288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain. 1999;82:15–22. doi: 10.1016/S0304-3959(99)00025-1. [DOI] [PubMed] [Google Scholar]
  • 44.Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal afferents in a migraine model. Nat Med. 2002;8:136–142. doi: 10.1038/nm0202-136. [DOI] [PubMed] [Google Scholar]
  • 45.Maneesri S, Patamanon J, Patumja S, Srkiatknachora A. Cortical spreading depression, meningeal inflammation and trigeminal nociception. Neuroreport. 2004;15:1623–1637. doi: 10.1097/01.wnr.0000134989.89428.3b. [DOI] [PubMed] [Google Scholar]
  • 46.Drummond PD, Lance JW. Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol. 1983;13:32–37. doi: 10.1002/ana.410130108. [DOI] [PubMed] [Google Scholar]
  • 47.Bousser M-G, Welch KMA. Relation between migraine and stroke. Lancet Neurol. 2005;4:533–542. doi: 10.1016/S1474-4422(05)70164-2. [DOI] [PubMed] [Google Scholar]
  • 48.Tietjen GE. Migraine a systemic vasculopathy. Cephalalgia. 2009;29:987–996. doi: 10.1111/j.1468-2982.2009.01937.x. [DOI] [PubMed] [Google Scholar]
  • 49.Stam AH, Haan J, Maagdenberg AMJM, Ferrari MD, Terwindt GM. Migraine and genetic and acquired vasculopathies. Cephalalgia. 2009;29:1006–1017. doi: 10.1111/j.1468-2982.2009.01940.x. [DOI] [PubMed] [Google Scholar]
  • 50.Bigal ME, Santanello NC, Buse DC, Kurth T, Golden WM, Robbins MS, Lipton RB. Migraine with and without aura are associated with cardiovascular disease. The American migraine prevalence and prevention study. Cephalalgia. 2009;29(Suppl 1):8. [Google Scholar]
  • 51.Artto VA, Meyso TM, Metso AJ, Putaala J, Haapaniemi E, Färkkilä M, et al. Migraine with aura is a risk factor for cervical artery dissection; a case control study. Cephalalgia. 2009;29(Suppl 1):114. doi: 10.1159/000313608. [DOI] [PubMed] [Google Scholar]
  • 52.Rubenstein SM, Peerdeman SM, Tulder MW, Riphagen I, Haldeman S. A systematic review of the risk factors for cervical artery dissection. Stroke. 2005;36:1575–1580. doi: 10.1161/01.STR.0000169919.73219.30. [DOI] [PubMed] [Google Scholar]
  • 53.Tzourio C, Benslamia L, Guillon B, Aïdi S, Bertrand M, Berthet K, et al. Migraine and the risk of cervical arterial dissection: a case-controlled study. Neurology. 2002;59:435–437. doi: 10.1212/wnl.59.3.435. [DOI] [PubMed] [Google Scholar]
  • 54.Tfelt-Hansen P, Le H. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache attacks? A review. J Headache Pain. 2009;10:137–143. doi: 10.1007/s10194-009-0112-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Kruit MC, Launer LJ, Ferrari MD, Buchem MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain. 2005;128:2068–2077. doi: 10.1093/brain/awh542. [DOI] [PubMed] [Google Scholar]
  • 56.Vanmolkot FH, Bortel LM, Hoon JN. Altered arterial function in migraine of recent onset. Neurology. 2007;68:1563–1570. doi: 10.1212/01.wnl.0000260964.28393.ed. [DOI] [PubMed] [Google Scholar]
  • 57.Goadsby PJ. Migraine, aura, and cortical spreading depression: why are we still talking about it? Ann Neurol. 2001;49:4–6. doi: 10.1002/1531-8249(200101)49:1<4::AID-ANA3>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  • 58.Olesen J, Friberg L, Olsen TS, Iversen HK, Lassen NA, Andersen AR, et al. Timing and topography of cerebral blood flow, aura and headache during migraine attacks. Ann Neurol. 1990;28:791–798. doi: 10.1002/ana.410280610. [DOI] [PubMed] [Google Scholar]
  • 59.Moskowitz MA, Nozahi K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci. 1993;13:1167–1177. doi: 10.1523/JNEUROSCI.13-03-01167.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Read SJ, Hirst WD, Upton N, Parsons A. Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. Brain Res. 2001;891:69–77. doi: 10.1016/S0006-8993(00)03191-7. [DOI] [PubMed] [Google Scholar]
  • 61.Kunkler PE, Kraig RP. Hippocampal spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. Hippocampus. 2003;13:835–844. doi: 10.1002/hipo.10139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Gursoy-Ozdemir Y, Qui J, Matsuoka N, Bolay H, Bernpohl D, Jin H et al (2004) Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113:1447–1455 [DOI] [PMC free article] [PubMed]
  • 63.Messlinger K. Migraine; where and how does the pain originate? Exp Brain Res. 2009;196:179–193. doi: 10.1007/s00221-009-1756-y. [DOI] [PubMed] [Google Scholar]
  • 64.Russell MB, Olesen J. A nosographic analysis of migraine aura in a general population. Brain. 1996;119:335–361. doi: 10.1093/brain/119.2.355. [DOI] [PubMed] [Google Scholar]
  • 65.Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura; a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 2009;8:723–728. doi: 10.1016/S1474-4422(09)70135-8. [DOI] [PubMed] [Google Scholar]
  • 66.Ebersberger A, Schaible HG, Averbech B, Richter F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol. 2001;49:7–13. doi: 10.1002/1531-8249(200101)49:1<7::AID-ANA4>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  • 67.Ingvardsen BK, Lauersen H, Olsen UB, Hansen AJ. Possible mechanism of c-fos expression in the trigeminal nucleus caudalis following cortical spreading depression Pain. 1997;72:407–415. doi: 10.1016/s0304-3959(97)00069-9. [DOI] [PubMed] [Google Scholar]
  • 68.Olesen J, Tfelt-Hansen P, Henriksen L, Larsen B (1981) Common migraine may not be initiated by cerebral ischemia. Lancet II:438-440 [DOI] [PubMed]
  • 69.Sanchez del Rio M, Bakker D, Wu O, Agosti R, Mitsikostas PD, Ostergaard L, et al. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia. 1999;19:701–707. doi: 10.1046/j.1468-2982.1999.019008701.x. [DOI] [PubMed] [Google Scholar]
  • 70.Benedittis G, Ferrari Da Passano C, Granata G, Lorenzetti A. CBF changes during headache-free periods and spontaneous/induced attacks in migraine with and without aura: a TCD and SPECT comparison study. J Neurosurg Sci. 1999;43:141–146. [PubMed] [Google Scholar]
  • 71.Andersson JL, Muhr C, Liljen A, Valind S, Lundberg PÅ, Långström B. Regional cerebral blood flow and oxygen metabolism during migraine with and without aura. Cephalalgia. 1997;27:570–579. doi: 10.1046/j.1468-2982.1997.1705570.x. [DOI] [PubMed] [Google Scholar]
  • 72.Bednarczyk EM, Remler B, Weikart C, Nelson AD, Reed RC. Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache. Neurology. 1998;50:1736–1740. doi: 10.1212/wnl.50.6.1736. [DOI] [PubMed] [Google Scholar]
  • 73.Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Posterior cerebral hypoperfusion in migraine without aura. Cephalalgia. 2008;28:856–862. doi: 10.1111/j.1468-2982.2008.01623.x. [DOI] [PubMed] [Google Scholar]
  • 74.Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading hypoperfusion during spontaneous migraine headache. N Eng J Med. 1994;331:1689–1692. doi: 10.1056/NEJM199412223312505. [DOI] [PubMed] [Google Scholar]
  • 75.Peters GA. Migraine: diagnosis and treatment with emphasis on the migraine-tension headache, provocative tests and use of rectal suppositories. Proc Staff Meet Mayo Clin. 1953;28:673–686. [PubMed] [Google Scholar]
  • 76.Sicuteri F, del Bene ED, Poggioni M, Bonnazzi A. Unmasking latent dysnociception in healthy subjects. Headache. 1987;27:180–185. doi: 10.1111/j.1526-4610.1987.hed2704180.x. [DOI] [PubMed] [Google Scholar]
  • 77.Tfelt-Hansen P, Daugaard D, Lassen LH, Iversen HK, Olesen J. Prednisolone reduces nitric oxide-induced migraine. Eur J Neurol. 2009;16:1106–1111. doi: 10.1111/j.1468-1331.2009.02654.x. [DOI] [PubMed] [Google Scholar]
  • 78.Thomsen LL, Iversen HK, Brinck TA, Olesen J. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia. 1993;13:395–399. doi: 10.1046/j.1468-2982.1993.1306395.x. [DOI] [PubMed] [Google Scholar]
  • 79.Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, et al. NO-induced migraine attacks: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106:461–470. doi: 10.1016/j.pain.2003.09.008. [DOI] [PubMed] [Google Scholar]
  • 80.Juhasz G, Zsombok T, Jakab B, Nemeth J, Szoksanyl J, Bagny G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attacks. Cephalalgia. 2005;25:179–183. doi: 10.1111/j.1468-2982.2005.00836.x. [DOI] [PubMed] [Google Scholar]
  • 81.Juhasz G, Zsombok T, Gonda X, Nagyne N, Modosne E, Bagdy G. Effects of autogenic training on nitroglycerin-induced headache. Headache. 2007;47:371–383. doi: 10.1111/j.1526-4610.2006.00718.x. [DOI] [PubMed] [Google Scholar]
  • 82.Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia. 1999;19:660–667. doi: 10.1046/j.1468-2982.1999.019007660.x. [DOI] [PubMed] [Google Scholar]
  • 83.Christiansen I, Daugaard D, Lykke Thomsen L, Olesen J. Glyceryl trinitrate induced headache in migraineurs—relation to attack frequency. Eur J Neurol. 2000;7:405–411. doi: 10.1046/j.1468-1331.2000.00094.x. [DOI] [PubMed] [Google Scholar]
  • 84.Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia. 1998;18:27–32. doi: 10.1046/j.1468-2982.1998.1801027.x. [DOI] [PubMed] [Google Scholar]
  • 85.Palmer JE, Guillard FL, Laurijssens BE, Wentz AL, Dixon RM, Williams PM (2010) A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia (in press)
  • 86.Schueren BJ, Lunnon MW, Laurijssens BE, Guillard F, Palmer J, Hecken A, et al. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in migraine? J Clin Pharmacol. 2009;49:281–290. doi: 10.1177/0091270008329548. [DOI] [PubMed] [Google Scholar]
  • 87.Hoye K, Laurijssens BE, Harnisch LO, Twormey CK, Dixon RM, Kirkham A, et al. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for twelve weeks in the prophylactic treatment of migraine. Cephahalgia. 2009;29:132. [Google Scholar]
  • 88.Akerman S, Williamson DJ, Kaube H, Goadsby PJ. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002;130:62–68. doi: 10.1038/sj.bjp.0704842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in the dura mater but not brain. J Neurosci. 1987;7:4129–4136. doi: 10.1523/JNEUROSCI.07-12-04129.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol. 1988;24:732–737. doi: 10.1002/ana.410240607. [DOI] [PubMed] [Google Scholar]
  • 91.Buzzi MG, Mokowitz MA. Evidence for the 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia. 1991;11:165–168. doi: 10.1046/j.1468-2982.1991.1104165.x. [DOI] [PubMed] [Google Scholar]
  • 92.Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, editors. The Headaches. 3. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 459–467. [Google Scholar]
  • 93.Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, editors. The Headaches. 3. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 469–503. [Google Scholar]
  • 94.Brändli P, Löffler BM, Breu V, Osterwalder R, Maire JP, Clozel M. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain. 1996;64:315–322. doi: 10.1016/0304-3959(95)00106-9. [DOI] [PubMed] [Google Scholar]
  • 95.Phebus LA, Johnson KW, Stengel PW, Lobb KL, Nixon JA, Hipskind PA. The non-peptide NK-1 receptor antagonists LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci. 1997;60:1553–1561. doi: 10.1016/S0024-3205(97)00121-5. [DOI] [PubMed] [Google Scholar]
  • 96.Connor HE, Bertin L, Gilles S, Beattie DT, Ward P, the GR295171 Clinical Study Group Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia. 1998;18:392. [Google Scholar]
  • 97.Diener HC. RPR100893, a substande-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia. 2003;23:183–185. doi: 10.1046/j.1468-2982.2003.00496.x. [DOI] [PubMed] [Google Scholar]
  • 98.Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute treatment of migraine: a crossover study. Cephalalgia. 1997;17:785–790. doi: 10.1046/j.1468-2982.1997.1707785.x. [DOI] [PubMed] [Google Scholar]
  • 99.Data J, Britch K, Westergaard N, Weihnuller F, Harris S, Swarz H, Silberstein S, Goldstein J, Ryan R, Saper J, Londborg P, Winner P, Klapper J. A double-blind study of ganaxolone in the treatment of migraine headaches with and without aura in premenopausal females. Headache. 1998;38:380. [Google Scholar]
  • 100.May A, Gijsman HJ, Wallnoefer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain. 1996;67:375–378. doi: 10.1016/0304-3959(96)03137-5. [DOI] [PubMed] [Google Scholar]
  • 101.Roon K, Diener HC, Ellis P, Hettiarachchi J, Poole P, Christiansen I, Ferrari MD, Olesen J. CP-122, 288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia. 1997;17:245. [Google Scholar]
  • 102.Earl NL, McDonald SA, Lowy Mt, 4991W93 Investigator Group Efficacy and tolerability of the neurogenic inflammation inhibitor, 4991W93, in the acute treatment of migraine. Cephalalgia. 1999;19:357. [Google Scholar]
  • 103.Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. Neurology. 2002;58:354–361. doi: 10.1212/wnl.58.3.354. [DOI] [PubMed] [Google Scholar]
  • 104.Schürks M, Kurth T, Jesus J, Jonsic M, Rosskopf D, Diener HC. Cluster headache: medical presentation, lifestyle factors, and medical treatment. Headache. 2006;46:1246–1254. doi: 10.1111/j.1526-4610.2006.00534.x. [DOI] [PubMed] [Google Scholar]
  • 105.Wöber C, Knopf A. Migrainous features in cluster headache. Cephalalgia. 2009;29(suppl 1):44. [Google Scholar]
  • 106.Silberstein SD, Niknam R, Rozen TD, Young WB. Cluster headache with aura. Neurology. 2000;54:219–221. doi: 10.1212/wnl.54.1.219. [DOI] [PubMed] [Google Scholar]
  • 107.Graham JR. Cluster headache. Headache. 1972;11:175–185. doi: 10.1111/j.1526-4610.1972.hed1104175.x. [DOI] [PubMed] [Google Scholar]
  • 108.Ekbom K, Svensson DA, Träff H, Waldenlind E. Age at onset and sex ratio in cluster headache: observation over three decades. Cephalalgia. 2002;22:94–100. doi: 10.1046/j.1468-2982.2002.00318.x. [DOI] [PubMed] [Google Scholar]
  • 109.Ekbom K, Svensson DA, Pedersen NL, Waldenlind E. Life time prevalence and concordance risk of cluster headache in the Swedish twin population. Neurology. 2006;67:798–803. doi: 10.1212/01.wnl.0000233786.72356.3e. [DOI] [PubMed] [Google Scholar]
  • 110.Ekbom K. A clinical comparison of cluster headache and migraine. Acta Neurol Scand. 1970;46(Suppl 41):1–48. [PubMed] [Google Scholar]
  • 111.Ekbom K, Waldenlind E, Tfelt-Hansen P. Cluster headache and aura. Headache. 2009;49:786–787. doi: 10.1111/j.1526-4610.2009.01417.x. [DOI] [PubMed] [Google Scholar]
  • 112.May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster headache. Lancet. 1998;352:275–278. doi: 10.1016/S0140-6736(98)02470-2. [DOI] [PubMed] [Google Scholar]
  • 113.May A, Bahra A, Büchel C, Frackowiak RS, Goadsby PJ. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology. 2000;55:1328–1335. doi: 10.1212/wnl.55.9.1328. [DOI] [PubMed] [Google Scholar]
  • 114.May A, Ashenburner J, Büchel C, McGonicle DJ, Friston KJ, Frackowiak RS, et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nat Med. 1999;5:836–838. doi: 10.1038/10561. [DOI] [PubMed] [Google Scholar]
  • 115.Lodi R, Oieranggeli G, Tonon C, Cevoli S, Testa C, Bivona G, et al. Study of hypothalamic metabolism in cluster headache by proton MR spectroscopy. Neurology. 2006;66:1264–1266. doi: 10.1212/01.wnl.0000208442.07548.71. [DOI] [PubMed] [Google Scholar]
  • 116.May A, Bahra A, Büchel C, Turner R, Goadsby PJ. Functional magnetic resonance imaging in spontaneous attacks of SUNCT: short-lasting unilateral neuralgiform headache with conjunctival injection and tearing. Ann Neurol. 1999;46:791794. doi: 10.1002/1531-8249(199911)46:5<791::AID-ANA18>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  • 117.Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep. 2003;7:308–318. doi: 10.1007/s11916-003-0052-y. [DOI] [PubMed] [Google Scholar]
  • 118.Matharu MS, Cohen AS, Frackowiak RS, Goadsby PJ. Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol. 2006;59:535–545. doi: 10.1002/ana.20763. [DOI] [PubMed] [Google Scholar]
  • 119.Matharu MS, Cohen AS, MGGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache. 2004;44:747–761. doi: 10.1111/j.1526-4610.2004.04141.x. [DOI] [PubMed] [Google Scholar]
  • 120.Yetkin E, Ozisik H, Ozcan C, Aksoy Y, Turban H. increased dilator response to nitrate and decreased flow-mediated dilatation in migraineurs. Headache. 2007;47:104–110. doi: 10.1111/j.1526-4610.2007.00657.x. [DOI] [PubMed] [Google Scholar]
  • 121.Villalon CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009;124:309–323. doi: 10.1016/j.pharmthera.2009.09.003. [DOI] [PubMed] [Google Scholar]
  • 122.Yetkin E, Ozisik H, Ozcan C, Aksoy Y, Turban H. Decreased endothelium-dependent vasodilatation in patients with migraine: a new aspect to vascular pathophysiology of migraine. Coron Artery Dis. 2006;17:29–33. doi: 10.1097/00019501-200602000-00005. [DOI] [PubMed] [Google Scholar]
  • 123.Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M-G (2009) CADASIL. Lancet Neurol 643–653 [DOI] [PubMed]
  • 124.Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731–739. doi: 10.1002/ana.410440506. [DOI] [PubMed] [Google Scholar]
  • 125.Moskowitz MA, Kurth T. Blood vessels, migraine, and stroke. Stroke. 2007;38:3117–3118. doi: 10.1161/STROKEAHA.107.495770. [DOI] [PubMed] [Google Scholar]
  • 126.Tfelt-Hansen P, Olesen J. Delayed hyperperfusion following migraine with a prolonged aphasic aura in a patient with CADASIL. Cephalalgia. 2008;28:899–902. doi: 10.1111/j.1468-2982.2008.01626.x. [DOI] [PubMed] [Google Scholar]
  • 127.Schwedt JJ (2009) Endothelial dysfunction in migraine. Cephalalgia 997–1002 [DOI] [PubMed]
  • 128.Lee ST, Chu K, Jung KM, Kim DH, Choe VN, Kim JH, et al. Decreased number of endothelial progenitor cells in patients with migraine. Neurology. 2008;70:1510–1517. doi: 10.1212/01.wnl.0000294329.93565.94. [DOI] [PubMed] [Google Scholar]
  • 129.Tiejten GE. Migraine as a systemic disorder. Neurology. 2007;68:1555–1556. doi: 10.1212/01.wnl.0000265415.18382.fb. [DOI] [PubMed] [Google Scholar]
  • 130.Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain (nociception) in migraine. Lancet Neurol. 2009;8:679–690. doi: 10.1016/S1474-4422(09)70090-0. [DOI] [PubMed] [Google Scholar]
  • 131.Horton BT, MacLean AR, WMcK Craig. A new syndrome of vascular headache: results of treatment with histamine: preliminary report. Proc Staff Meet Mayo Clinic. 1939;14:257–260. [Google Scholar]
  • 132.Kudrow L (1980) Cluster headache. Mechanisms and management. Oxford University Press, New York
  • 133.Horton BT. Histaminic cephalalgia; differential diagnosis and treatment. Proc Staff Meet Mayo Clin. 1956;1:325–333. [PubMed] [Google Scholar]
  • 134.May A. The role of imaging in the pathophysiology and diagnosis of headache. Current Opin Neurol. 2005;18:293–297. doi: 10.1097/01.wco.0000169748.44782.af. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES